ORIC Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. furnished this Form 8-K on November 6, 2023, under Item 2.02 to announce financial results for the fiscal quarter ended September 30, 2023. The filing references a related press release as Exhibit 99.1, but the press release text and underlying financial results are not included in the provided filing content.
Financial Metrics
The filing text does not provide clear values for revenue, net income or loss, operating expenses, cash flow, cash and equivalents, investments, debt, liquidity, margins, or other financial metrics.
Changes Versus Prior Comparable Period
No quantitative or qualitative comparison with the prior-year or prior-quarter period is provided in the filing text.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide guidance, updated outlook, management commentary, risk disclosures, contingencies, or unusual items. Item 2.02 and the related exhibit are furnished rather than filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated by reference.
Key Facts to Verify
- Obtain and review Exhibit 99.1, the November 6, 2023 press release, for the quarter’s financial results and management commentary.
- Verify reported cash, investments, operating cash burn, and expected liquidity runway as of September 30, 2023.
- Verify research and development expenses, general and administrative expenses, net loss, and loss per share.
- Review any clinical, regulatory, financing, or pipeline updates included in the press release.
- Confirm whether the reported results were subsequently incorporated into a filed SEC report or other public disclosure.